LYST THERAPEUTICS LLC
Columbus, OH · Biotech · Defunct
Monoclonal antibody (LystaMab) that inhibits the LYST protein to prevent post-surgical cardiac adhesions
- Grants
- $1.5M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Targeted LystaMab Therapy to Optimize Tissue Engineered Vascular Graft Performance | $222,703 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted LystaMab Therapy to Optimize Tissue Engineered Vascular Graft Performance | $222,703 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · LystaMab Immunotherapy to Inhibit Pericardial Adhesions | $225,342 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · LystaMab Immunotherapy to Inhibit Pericardial Adhesions | $225,342 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Development of a LystaMab coated pericardial adhesion barrier | $308,896 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Development of a LystaMab coated pericardial adhesion barrier | $308,896 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2814 | TAMBO, INC. | — | — |
| 2815 | Diapin Therapeutics LLC | — | — |
| 2816 | Mineralys Therapeutics, Inc. | — | $118M |
| 2817 | LYST THERAPEUTICS LLC | — | — |
| 2818 | Relation Therapeutics | — | $116M |
| 2819 | STEL Technologies, LLC | — | — |
| 2820 | Passage Bio | — | $110M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.